Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Abivax S.A. (ABVX.PA)
EUR118.90
-1.20 (-1.00%)
FR PAR Healthcare Biotechnology
Address
5, rue de la Baume 75008
Paris, FR
Paris, FR
CEO
Marc de Garidel
Website
abivax.com
IPO
2015-06-26
ISIN FR0012333284
Also trades on
Euronext Paris · ABVX.PA (EUR)
London Stock Exchange · 0RA9.L (EUR)
NASDAQ Global Market · ABVX (USD)
Other OTC · AAVXF (USD)
Description
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR118.90
-1.20 (-1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
280.9K
Beta
-0.20
Float Shares
66.12M
Free Float %
83.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.60% | +5.88% | +14.38% | +6.81% | -1.79% | -8.80% | +1,944.69% | +506.63% | +281.91% | +999.10% | +422.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
118.90
DCF (Unlevered)
7.11
-94.0%
DCF (Levered)
6.97
-94.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
38.30
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0% Q4'25: -189.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-72.5% Q4'25: -69.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q4'25: +4,737.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%— Q4'25: +7,780.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +1,456.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+10.3% Q4'25: +38.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q4'25: -0.05× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 5 EPS Ana. |
Dec 2027 14 Rev. Ana. 4 EPS Ana. |
Dec 2028 9 Rev. Ana. 3 EPS Ana. |
Dec 2029 4 Rev. Ana. 1 EPS Ana. |
Dec 2030 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
228.0K
est: 2.46M (-90.7%)
|
151.0K
est: 28.19M (-99.5%)
|
356.0K
est: 151.0K (+135.8%)
|
815.0K
est: 700.0K (+16.4%)
|
37.0K
est: 666.7K (-94.5%)
|
4.58M
est: 1.65M (+177.8%)
|
4.62M
est: 9.03M (-48.8%)
|
10.79M
est: 8.54M (+26.4%)
|
—
est: 6.10M (-100.0%)
|
2.64M
2.64M – 2.64M
-56.8% YoY
|
122.83M
120.36M – 125.29M
+4,552.4% YoY
|
595.37M
595.37M – 595.37M
+384.7% YoY
|
1.19B
1.19B – 1.19B
+100.4% YoY
|
1.60B
1.60B – 1.60B
+34.0% YoY
|
| EBITDA |
-18.12M
est: -2.46M (-635.9%)
|
-17.73M
est: -28.19M (+37.1%)
|
-14.06M
est: -151.0K (-9,209.3%)
|
-19.23M
est: -700.0K (-2,646.7%)
|
-42.20M
est: -666.7K (-6,229.2%)
|
-53.32M
est: -1.65M (-3,131.2%)
|
-133.21M
est: -5.42M (-2,358.3%)
|
-167.68M
est: -5.12M (-3,172.7%)
|
-249.55M
est: -3.66M (-6,713.4%)
|
-1.58M
-1.58M – -1.58M
+56.8% YoY
|
-73.70M
-75.18M – -72.22M
-4,552.4% YoY
|
-357.22M
-357.22M – -357.22M
-384.7% YoY
|
-715.94M
-715.94M – -715.94M
-100.4% YoY
|
-959.65M
-959.65M – -959.65M
-34.0% YoY
|
| EBIT |
-18.26M
est: -2.46M (-641.5%)
|
-17.94M
est: -28.19M (+36.4%)
|
-14.07M
est: -151.0K (-9,219.9%)
|
-19.33M
est: -700.0K (-2,660.9%)
|
-42.35M
est: -666.7K (-6,252.6%)
|
-53.80M
est: -1.65M (-3,160.6%)
|
-133.91M
est: -5.42M (-2,371.4%)
|
-168.78M
est: -5.12M (-3,194.2%)
|
-250.63M
est: -3.66M (-6,742.7%)
|
-1.58M
-1.58M – -1.58M
+56.8% YoY
|
-73.70M
-75.18M – -72.22M
-4,552.4% YoY
|
-357.22M
-357.22M – -357.22M
-384.7% YoY
|
-715.94M
-715.94M – -715.94M
-100.4% YoY
|
-959.65M
-959.65M – -959.65M
-34.0% YoY
|
| Net Income |
-15.96M
est: -109.70M (+85.5%)
|
-14.31M
est: -66.20M (+78.4%)
|
-11.22M
est: -74.57M (+85.0%)
|
-15.82M
est: -100.24M (+84.2%)
|
-42.45M
est: -180.84M (+76.5%)
|
-60.74M
est: -166.06M (+63.4%)
|
-147.74M
est: -218.05M (+32.2%)
|
-176.24M
est: -185.18M (+4.8%)
|
-336.10M
est: -271.16M (-23.9%)
|
-286.60M
-322.96M – -156.46M
-5.7% YoY
|
-188.88M
-227.46M – -126.54M
+34.1% YoY
|
-8.21M
-17.31M – 194.20M
+95.7% YoY
|
453.10M
453.10M – 453.10M
+5,621.8% YoY
|
567.04M
567.04M – 567.04M
+25.1% YoY
|
| SGA |
13.87M
est: 1.25B (-98.9%)
|
3.56M
est: 14.32B (-100.0%)
|
3.78M
est: 76.69M (-95.1%)
|
4.30M
est: 355.50M (-98.8%)
|
5.58M
est: 338.57M (-98.4%)
|
7.49M
est: 837.96M (-99.1%)
|
28.82M
est: 294.88M (-90.2%)
|
38.90M
est: 278.83M (-86.0%)
|
71.79M
est: 199.32M (-64.0%)
|
86.20M
86.20M – 86.20M
-56.8% YoY
|
4.01B
3.93B – 4.09B
+4,552.4% YoY
|
19.44B
19.44B – 19.44B
+384.7% YoY
|
38.96B
38.96B – 38.96B
+100.4% YoY
|
52.22B
52.22B – 52.22B
+34.0% YoY
|
| EPS |
-1.65
est: -1.74 (+5.2%)
|
-1.48
est: -1.05 (-41.0%)
|
-1.14
est: -1.18 (+3.6%)
|
-1.56
est: -1.59 (+1.9%)
|
-2.75
est: -2.87 (+4.1%)
|
-3.18
est: -2.53 (-25.5%)
|
-3.43
est: -3.14 (-9.4%)
|
-2.80
est: -2.66 (-5.1%)
|
-4.83
est: -3.90 (-23.8%)
|
-3.38
-4.65 – -2.25
+13.2% YoY
|
-2.81
-3.27 – -1.82
+17.1% YoY
|
1.25
-0.25 – 2.79
+144.5% YoY
|
6.52
6.52 – 6.52
+421.7% YoY
|
8.16
8.16 – 8.16
+25.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-318.48M
OE per share TTM
-4.89
Owner's Yield
-4.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
31.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
79.69M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marc de Garidel | Chief Executive Officer & Director | 1M | male |
| Didier Blondel | EVice President, Chief Financial Officer & Board Secretary | — | male |
| Douglas Jacobstein | Senior VP & Global Head of Clinical Development | — | — |
| Hema Keshava | Senior Vice President of Finance | — | — |
| Ida Hatoum | Chief People & Compliance Officer | — | female |
| Jerome Denis | Executive Vice President of Process Development & Manufacturing | — | male |
| Kevin Shan | Vice President & Global Head of Biometrics | — | — |
| Mary Mantock | Senior VP & Global Head of Regulatory Affairs | — | — |
| Nadege Briancon-Eris | Senior VP & Global Head of Program Management | — | female |
| Patrick Malloy | Senior Vice President of Investor Relations | — | male |
| Chris Rabbat | Vice President & Global Head of Medical Affairs | — | — |
| Pierre Courteille | Chief Business Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABVX.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
